🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

24 recruiting trials

for Urothelial Carcinoma (UC)

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA NCT07413523NA1 site📍 Rozzano Istituto Clinico Humanitas · Tests: SBRT 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018Phase 1, Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC NCT07671092EARLY Phase 16 sites📍 St Leonards📍 Nedlands📍 Perth RayzeBio, Inc. · Tests: RYZ211/212 Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification NCT07888374n/a1 site📍 Shanghai Ruijin Hospital Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194Phase 1, Phase 26 sites📍 Denver📍 Miami📍 Boston ModeX Therapeutics, An OPKO Health Company · Tests: MDX2001 Korean Prospective Upper Tract Urothelial Carcinoma Cohort NCT07452432n/a1 site📍 Seoul Samsung Medical Center · Tests: Peripheral blood collection for ctDNA analysis A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma NCT06982794n/a1 site📍 Milan IRCCS San Raffaele DK222 Study at Hopkins NCT07140315Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: [18F]DK222 radiotracer A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors NCT07439120EARLY Phase 11 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483Phase 1122 sites📍 Phoenix📍 Tucson📍 Palo Alto Exelixis · Tests: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites📍 Orlando📍 Boston📍 Oklahoma City Sutro Biopharma, Inc. · Tests: STRO-006, Pembrolizumab Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis NCT07614594n/a1 site📍 Zhengzhou Henan Provincial People's Hospital Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging NCT07602010n/a1 site📍 Oslo Oslo University Hospital Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer NCT07673016n/a23 sites📍 Oceanside📍 San Diego📍 San Jose Convergent Genomics, Inc. Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence NCT06682728Phase 21 site📍 Orange University of California, Irvine · Tests: Sacituzumab Govitecan (SG), Nivolumab Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma NCT07441499n/a1 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Multi-Component Liquid Biopsy for Urothelial Carcinoma A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma NCT07815665Phase 2, Phase 37 sites📍 Phoenix📍 Los Angeles📍 Washington D.C. Summit Therapeutics · Tests: Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab, Ivonescimab Dose 2, Ivonescimab RP3D A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors NCT07518043Phase 17 sites📍 Fuzhou📍 Hangzhou📍 Luoyang Shanghai Henlius Biotech · Tests: HLX18, OPDIVO® Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples NCT07848854Phase 21 site📍 Kunming Yunnan Cancer Hospital · Tests: TTP-ICG fluorescent probe Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer NCT07756437n/a1 site📍 Ghent AZ Sint-Lucas Gent
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy